Contact: Katie Glenn, email@example.com, 202-375-6472
WASHINGTON (Apr 03, 2020) -
Data from the American College of Cardiology's NCDR was the source of several studies published and presented in recent months, including studies examining improvements in ambulatory cardiovascular care processes, a lack of change in racial disparities for myocardial infarction outcomes since the advent of the Hospital Readmissions Reduction Program, as well as studies presented at ACC.20/WCC Virtual.
PINNACLE Registry Study Shows Improvements in Ambulatory CV Care Processes
Between 2013 and 2017, care processes generally improved for patients in ACC and Veradigm's PINNACLE Registry, according to a review article published Jan. 6 in the Journal of the American College of Cardiology. Read more.
NCDR Study Compares Hospitalization Rates, Medicare Costs Pre- vs. Post-TMVR
Patients undergoing transcatheter mitral valve repair (TMVR) may experience a decrease in hospitalizations for cardiovascular diagnoses and heart failure (HF) and lower HF-related Medicare costs in the year following the procedure, according to a study published Dec. 2 in JACC: Cardiovascular Interventions. Using data from the STS/ACC TVT Registry, Jennifer A. Rymer, MD, MBA, et al., analyzed outcomes of 4,970 patients to assess the real-world impact of TMVR on hospitalizations and Medicare costs pre- vs. post-TMVR. Read more.
TAVR May Be Effective For AR Treatment in Patients Unable to Undergo SAVR, NCDR Study Suggests
Transcatheter aortic valve replacement (TAVR) may be appropriate in patients with aortic regurgitation (AR) who are not candidates for surgical aortic valve replacement, according to a study published recently in the American Journal of Cardiology. Using data from the STS/ACC TVT Registry, Saif Anwaruddin, MD, et al., evaluated outcomes in 230 patients who underwent TAVR for native AR using a commercially available self-expanding valve system. Read more.
NCDR Study Finds No Change in Racial Disparities in MI Outcomes Following HRRP Implementation
Racial disparities in 30-day readmission and mortality rates among Medicare beneficiaries hospitalized with myocardial infarction (MI) did not change following implementation of the Centers for Medicare and Medicaid Services Hospital Readmissions Reduction Program, according to a study published Jan. 8 in JAMA Cardiology. Ambarish Pandey, MD, MSCS, et al., used data from ACC's Chest Pain-MI Registry to assess trends in 30-day readmission and mortality rates among black and nonblack patients hospitalized for MI from 2008 through 2016. Read more.
NCDR Study Finds Clopidogrel Used More Often Than Newer Antiplatelet Agents
The antiplatelet agent clopidogrel may be used more often that newer antiplatelet therapies ticagrelor and prasugrel following PCI procedures, according to a study published recently in the American Journal of Cardiology. Using data from ACC and Veradigm's PINNACLE Registry, Umair Khalid, MD, et al., evaluated patient characteristics and provider/practice factors associated with prescriptions for newer antiplatelet agents in patients who underwent PCI with a drug-eluting stent and received prescriptions for dual antiplatelet therapy. Read more.
Major Adverse Events More Common After PVI in Patients With CLI, NCDR Study Shows
Patients with critical limb ischemia (CLI) undergoing peripheral vascular intervention (PVI) may be more likely to experience in-hospital major adverse cardiovascular and limb events, according to a review letter published Feb. 10 in the Journal of the American College of Cardiology. Jennifer A. Rymer, MD, MBA, et al., used data from ACC's PVI Registry to compare in-hospital major adverse cardiovascular events and in-hospital major adverse limb events among patients with CLI vs. claudication undergoing PVI. Read more.
NCDR Study Shows Increasing Ticagrelor Use With Hospital, Patient Variations
Use of the P2Y12 inhibitor ticagrelor has steadily increased since its 2011 approval by the U.S. Food and Drug Administration, with variations based on patient- and hospital-level characteristics, according to a study published Jan. 15 in the International Journal of Cardiology. Benjamin A. Rodwin, MD, et al., reviewed data from ACC's Chest Pain-MI Registry to describe trends in the use of the P2Y12 inhibitors clopidogrel, ticagrelor and prasugrel among 362,354 myocardial infarction patients treated at 801 hospitals from 2009 through 2017. Read more.
Intravascular Microaxial LVAD Associated With Higher Risk of In-Hospital Mortality, Bleeding, NCDR Study Shows
In AMI patients complicated by cardiogenic shock (AMI-CS) undergoing PCI, use of an intravascular microaxial left ventricular assist device may be associated with higher rates of in-hospital adverse events compared with an intra-aortic balloon pump, according to a study published Feb. 10 in the Journal of the American Medical Association. Preliminary results were previously presented as a Late-Breaking Clinical Trial during AHA 2019 in Philadelphia. Sanket Dhruva, MD, MHS, FACC, et al., looked at data from ACC's CathPCI Registry and Chest Pain-MI Registry to assess mechanical circulatory support device utilization from October 2015 to December 2017 among patients with AMI-CS undergoing PCI. Read more.
Is Quality of CV Care Associated With Hospital Performance in Value-Based Care Programs?
Hospitals that receive awards for high-quality cardiovascular care from the ACC or American Heart Association (AHA) quality improvement initiatives may be less likely to receive financial incentives under federal value-based care programs, according to a study published Feb. 19 in JAMA Cardiology. Rishi K. Wadhera, MD, MPP, MPhil, et al., looked at whether hospitals that received awards for high-quality care from the ACC or AHA were less likely to be penalized under the Hospital Readmissions Reduction Program or Hospital Value-Based Purchasing Program. Read more.
About Half of Repeat PCIs Attributed to Original Stent Placement, NCDR Study Shows
About half of repeat PCIs following implantation of a drug-eluting stent could be attributed to the same coronary artery as the original stent placement, according to a study published Feb. 16 in the Journal of the American Heart Association. Sanket S. Dhruva, MD, MHS, FACC, et al., used ACC's CathPCI Registry and Medicare claims data to determine the extent to which adverse events identified with claims data could be attributed to a previously placed stent. Read more.
Adverse Events Decrease as Use of Coronary Atherectomy For PCI Increases, NCDR Study Finds
Use of coronary atherectomy (CA) for PCI has increased over time and may be associated with a decreased risk of major adverse cardiovascular events, according to a study published Jan. 24 in Circulation: Cardiovascular Interventions. Nirat Beohar, MD, FACC, et al., used data from ACC's CathPCI Registry to assess trends in frequency of CA use, hospital variability and outcomes with CA in patients undergoing PCI. The researchers used four time-based intervals, ranging from 2009 to 2016, to look at outcomes and patient and hospital variables over the study period. Read more.
Conscious Sedation Associated With Improved TAVR Outcomes vs. General Anesthesia
The use of conscious sedation for transcatheter aortic valve replacement (TAVR) may be associated with improved outcomes compared with general anesthesia, according to results of a study presented during ACC.20/WCC and simultaneously published March 16 in JACC: Cardiovascular Interventions. Using data from the STS/ACC TVT Registry, Neel M. Butala, MD, MBA, et al., looked at the relationship between conscious sedation vs. general anesthesia and TAVR outcomes based on hospital proportion of conscious sedation use. The researchers also examined variations in the use of conscious sedation for TAVR across hospitals and over time. Read more.
NCDR data and news was also previously highlighted. Read more:
- WATCHMAN Shows Favorable Safety Record in US Clinical Practice
- Study Finds Room for Improvement in TAVR Outcomes Across US
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.